MA29765B1 - Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire - Google Patents

Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire

Info

Publication number
MA29765B1
MA29765B1 MA30723A MA30723A MA29765B1 MA 29765 B1 MA29765 B1 MA 29765B1 MA 30723 A MA30723 A MA 30723A MA 30723 A MA30723 A MA 30723A MA 29765 B1 MA29765 B1 MA 29765B1
Authority
MA
Morocco
Prior art keywords
complementary system
epithelial cells
extracellular matrix
moraxella catarrhalis
interaction
Prior art date
Application number
MA30723A
Other languages
English (en)
Inventor
Arne Forsgren
Kristian Riesbeck
Original Assignee
Arne Forsgren Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arne Forsgren Ab filed Critical Arne Forsgren Ab
Publication of MA29765B1 publication Critical patent/MA29765B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES PROTÉINES MATRICIELLES EXTRACELLULAIRES DE MORAXELLA CATARRHALIS ET LA CAPACITÉ D'INTERAGIR AVEC DES CELLULES ÉPITHÉLIALES VIA UNE FIBRONECTINE ET UNE LAMININE ASSOCIÉE À LA CELLULE ET, ÉGALEMENT LEUR CAPACITÉ D'INHIBER LE SYSTÈME COMPLÉMENTAIRE. CES PROTÉINES EXTRACELLULAIRE CONVIENNENT POUR LA PRÉPARATION DE VACCINS. CETTE INVENTION CONCERNE DES PEPTIDES INTERAGISSANT AVEC LA FIBRONECTINE, LA LAMININE ET LE SYSTÈME COMPLÉMENTAIRE.
MA30723A 2005-08-10 2008-03-07 Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire MA29765B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70674505P 2005-08-10 2005-08-10
US70714805P 2005-08-11 2005-08-11

Publications (1)

Publication Number Publication Date
MA29765B1 true MA29765B1 (fr) 2008-09-01

Family

ID=37727738

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30723A MA29765B1 (fr) 2005-08-10 2008-03-07 Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire

Country Status (15)

Country Link
US (7) US8092811B2 (fr)
EP (4) EP2548885B1 (fr)
JP (2) JP5269594B2 (fr)
KR (1) KR20080042865A (fr)
AU (1) AU2006277076B2 (fr)
BR (1) BRPI0614734A2 (fr)
CA (1) CA2618554C (fr)
EA (1) EA014352B1 (fr)
ES (1) ES2537274T3 (fr)
IL (2) IL189258A0 (fr)
MA (1) MA29765B1 (fr)
MX (1) MX2008002037A (fr)
NO (1) NO20080259L (fr)
NZ (1) NZ565651A (fr)
WO (1) WO2007018463A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014352B1 (ru) * 2005-08-10 2010-10-29 Арне Форсгрен Аб Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
EA201391669A1 (ru) * 2011-05-11 2014-04-30 Риесбекк Хелткеэр Свиден Аб Белок f - новый адгезин haemophilus influenzae, способный связывать ламинин и витронектин
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
JP2020515587A (ja) 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 免疫原性組成物、使用及び処置方法
WO2019034575A1 (fr) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa Procédés d'amplification des réponses immunitaires
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
EP4010014A1 (fr) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Composition immunogène
CA3148928A1 (fr) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Procede de preparation d'une composition comprenant un polypeptide de proteine d
WO2021048159A1 (fr) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Dosage
EP4294433A1 (fr) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Composition immunogène, utilisation et procédés
CN114409756B (zh) * 2022-01-21 2023-06-09 中国科学院海洋研究所 一种牙鲆补体成分C3（PoC3）的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) * 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
CN1159441C (zh) * 1996-12-20 2004-07-28 德克萨斯州大学系统董事会 粘膜炎莫拉菌的uspa1和uspa2抗原
GB0003502D0 (en) 2000-02-15 2000-04-05 Smithkline Beecham Sa Vaccine
DK2088197T3 (en) 2000-10-02 2016-08-01 Id Biomedical Corp Quebec Haemophilus influenzae antigens and corresponding DNA fragments
SE0102410D0 (sv) 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
EP1409013B1 (fr) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccins comprenant des adjuvants aluminium et histidine
GB0222764D0 (en) 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EA014352B1 (ru) 2005-08-10 2010-10-29 Арне Форсгрен Аб Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
CN104436180B (zh) 2006-01-17 2021-08-31 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)

Also Published As

Publication number Publication date
US20100062027A1 (en) 2010-03-11
WO2007018463A3 (fr) 2007-05-10
KR20080042865A (ko) 2008-05-15
NO20080259L (no) 2008-05-13
JP5269594B2 (ja) 2013-08-21
US10183071B2 (en) 2019-01-22
US20160318979A1 (en) 2016-11-03
ES2537274T3 (es) 2015-06-05
EA014352B1 (ru) 2010-10-29
US8323667B2 (en) 2012-12-04
JP2013150614A (ja) 2013-08-08
EP1913019A2 (fr) 2008-04-23
US20170281746A1 (en) 2017-10-05
IL216703A0 (en) 2012-01-31
CA2618554C (fr) 2017-03-07
CA2618554A1 (fr) 2007-02-15
US20190117757A1 (en) 2019-04-25
NZ565651A (en) 2012-01-12
BRPI0614734A2 (pt) 2011-04-12
US20130129763A1 (en) 2013-05-23
EP1913019B1 (fr) 2014-12-31
EP2548885A2 (fr) 2013-01-23
IL189258A0 (en) 2008-08-07
JP2009504152A (ja) 2009-02-05
US10786562B2 (en) 2020-09-29
EP3305807B1 (fr) 2024-08-21
EA200800565A1 (ru) 2008-10-30
US9657067B2 (en) 2017-05-23
US8092811B2 (en) 2012-01-10
US9255127B2 (en) 2016-02-09
EP2548884A3 (fr) 2013-05-01
AU2006277076A1 (en) 2007-02-15
EP2548884B1 (fr) 2017-08-02
MX2008002037A (es) 2008-03-27
EP2548885A3 (fr) 2013-05-01
US8895030B2 (en) 2014-11-25
AU2006277076B2 (en) 2012-03-29
EP3305807A1 (fr) 2018-04-11
JP5763113B2 (ja) 2015-08-12
EP2548885B1 (fr) 2017-10-18
US20120148614A1 (en) 2012-06-14
US20150140026A1 (en) 2015-05-21
EP2548884A2 (fr) 2013-01-23
WO2007018463A2 (fr) 2007-02-15

Similar Documents

Publication Publication Date Title
MA29765B1 (fr) Interaction de moraxella catarrhalis avec des cellules epitheliales, des proteines matricielles extracellulaires et le systeme complementaire
JP7166022B2 (ja) 治療用変異体アルファ２－マクログロブリン組成物
Riedle et al. Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/γ-secretase activity
ES2717751T3 (es) Polipéptidos efectores de la subunidad A de la toxina de Shiga resistentes a la escisión por proteasa y moléculas dirigidas a células que los comprenden
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
Mitova et al. Cyclic peptides from a Ruegeria strain of bacteria associated with the sponge Suberites domuncula
TW200740844A (en) Novel MAdCAM antibodies
Metzger et al. Modular poly (ethylene glycol) matrices for the controlled 3D‐localized osteogenic differentiation of mesenchymal stem cells
GB0329825D0 (en) Biological products
Gebhard et al. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
WO2008030539A3 (fr) Méthodes et compositions à base de conjugués toxine diphtérique-interleukine 3
AR065373A1 (es) Proteinas de fusion de inmunoglobulina y metodos de elaboracion
BRPI0520677A2 (pt) identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
MA30474B1 (fr) Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee.
Williams et al. Neopetrosiamides, peptides from the marine sponge Neopetrosia sp. that inhibit amoeboid invasion by human tumor cells
NO20064134L (no) Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav
Smith et al. Emerging strategies to access peptide macrocycles from genetically encoded polypeptides
TN2009000194A1 (en) Novel antiproliferation antibodies
KR20190087461A (ko) p53 분해 유도 분자 및 의약 조성물
Kawaguchi et al. Identification of cellular proteins interacting with octaarginine (R8) cell-penetrating peptide by photo-crosslinking
Junk et al. Total synthesis and configurational revision of mozamide A, a hydroxy-brunsvicamide
JP7061800B2 (ja) Ｒａｓタンパク質分解誘導分子及び医薬組成物
Basler et al. On the role of the immunoproteasome in transplant rejection
Zhang et al. Exploring and exploiting plant cyclic peptides for drug discovery and development